ly3298176 tirzepatide Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Bridging the gap between GLP1-receptor
Pay in 4 interest-free payments of $5.93 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30



















![Tirzepatide vs. Semaglutide: Which GLP-1 Better Preserves Muscle? [SURMOUNT-5 Data]](https://www.clinicalnutritioncenter.com/wp-content/uploads/2026/04/research-image-2026-04-10-1024x559.jpg)





